Objective: To characterize the molecular basis of a novel fast-channel congenital myasthenic syndrome.
METHODS Protocol approval and consents. The investigations described in this study were approved by the Institutional Review Board of the Mayo Clinic. The patient's father gave informed consent for the genetic studies.
Molecular genetic studies. Molecular genetic studies were performed by previously described methods. 4 We directly sequenced CHRNA1, CHRNB1, CHRND, and CHRNE using genomic DNA extracted from blood. The p.Trp55Arg mutation detected in CHRNE was traced with allele-specific PCR in family members and was not present in 400 normal alleles of 200 unrelated controls. Expression of the mutant AChR in HEK cells is described in appendix e-1 on the Neurology ® Web site at www.neurology.org.
Patch-clamp recordings from AChRs expressed in HEK cells at low and high concentrations of ACh were obtained in the cell-attached configuration at a membrane potential of Ϫ80 mV at 22°C and with bath and pipette solutions containing (mM) KCl 142, NaCl 5.4, CaCl 2 1.8, MgCl 2 1.7, HEPES 10, pH 7.4. 4 The recordings and their analyses were performed by previously described methods (see reference 4 and appendix e-2).
RESULTS Clinical data. An 8-year-old boy born to asymptomatic second-degree cousins had severe myasthenic symptoms since birth. He is wheelchair bound; pyridostigmine therapy enables him to take a few steps. He has a 19% decremental EMG response in the trapezius muscle, and single fiber EMG reveals a mean jitter of 102 s (normal Ͻ50 s). Three similarly affected siblings died in infancy, 1 similarly affected brother is alive, and 2 other siblings are unaffected.
Mutation analysis. Sequencing of the each AChR subunit gene revealed a homozygous replacement of Trp by Arg in CHRNE at codon 55: p.W55R (c.163TϾC) (reference sequence NM_000080.3). The mutated Trp is conserved across the AChR , ␥, and ␦ subunits of all species and is located at the ␣/ agonist binding site interface (figure 1). No DNA was available from other family members but homozygosity of the proband is strong evidence for the asymptomatic parents being carriers and for transmission by recessive inheritance.
Expression studies. 125 I-␣-bungarotoxin binding studies revealed that the mutant receptor expressed at 86% of wild-type. Hence the deleterious effects of the mutation likely arise from altered AChR activation kinetics.
To examine kinetic consequences of the W55R mutation, we recorded single channel currents from HEK cells expressing mutant and wild-type AChR at a low concentration of ACh (50 nM). The resulting channel events appear as isolated openings or as several openings in quick succession, called bursts (figure 2 and table 1). The burst duration histograms reveal 2 exponential components for W55R-AChR and 3 for wild-type AChR. For wild-type AChR, the longest component of bursts has a mean duration of 3.31 msec, but for W55R-AChR the corresponding value is only 0.37 msec, predicting fast decay of the synaptic current.
To identify kinetic steps in AChR activation altered by W55R, we recorded channel openings over a range of ACh concentrations and constructed histograms of open and closed dwell times ( figure 3 ). Wild-type AChR generates well defined clusters of openings with 10 M ACh but W55R-AChR does so only with 100 M and higher concentrations of ACh. The mutant clusters have longer closed times with fewer and briefer openings than wild-type. For both wild-type and W55R-AChRs, the longest closed-time component shifts to the left with increasing ACh concentration, but the mutant histograms shift less than the wild-type.
To determine the consequences of the mutations on rate constants underlying receptor activation, we analyzed the global set of open and closed dwell times according to Scheme 1 shown below:
Here, 2 agonists (A) bind to the receptor (R) with association rate constants k ϩ1 and k ϩ2 , and dissociate with rate constants k Ϫ1 and k Ϫ2 . The receptor with 2 agonists bound opens with rate constant ␤ and closes with rate constant ␣. Asterisk indicates the open state and R B indicates the blocked state. At high concentrations, ACh blocks the open channel with rate constant k ϩb , and the channel unblocks with rate constant k -b . The fitted rate constants allow calculation of the equilibrium dissociation constants so that K 1 ϭ k Ϫ1 /k ϩ1 , K 2 ϭ k Ϫ2 /k ϩ2 , K B ϭ k Ϫb /k ϩb , and the channel gating equilibrium constant ϭ ␤/␣. For wild-type human AChR, the ␣/␦ binding site has a higher agonist affinity than the ␣/ binding site, 5 so that the first binding step occurs at the ␣/␦ site. For the mutant receptor, we constrained k ϩ1 and k Ϫ1 to the wild-type values with the assumption that the 2 binding sites are independent and affinity of ACh for the ␣/␦ binding site is unchanged by the mutation. This scheme together with fitted rate constants describes well the closed and open duration histograms of wild-type and mutant receptors. The fitted rate constants in table 2 indicate that the W55R increases the dissociation constant of the diliganded receptor 30-fold by decreasing the forward binding rate constant 10-fold and increasing the dissociation rate constant 3-fold, and reduces gating efficiency 75-fold mainly by decreasing the chan- 
DISCUSSION
The correct diagnosis of a CMS is important because it dictates appropriate therapy. In most CMS clinical, EMG, and molecular genetic studies point to the correct diagnosis but diagnosis of a fast-channel CMS requires in vitro microelectrode or single-channel patch-clamp recordings. Moreover, only single-channel patch-clamp recordings can elucidate the mechanistic consequences of the identified mutation.
We detected a homozygous missense mutation of an aromatic Trp residue in the subunit at the ␣/ binding site of AChR in a highly fatal form of CMS. To our knowledge, no spontaneous mutation of an aromatic residue in the binding pocket of AChR has been reported to date. W55R-AChR expresses well in HEK cells, has very low apparent ACh affinity for the ␣/ site, and exhibits markedly reduced apparent gating efficiency. The findings underline the impor-tance of the aromatic residues that shroud the AChR agonist binding sites. 8 -10 A contribution of Trp55 in the ␥, ␦, and subunits to agonist binding has been previously emphasized. 10 -12 Single-channel recordings from mouse W55R-AChR expressed in HEK cells yielded a very low P open , although kinetic analysis was not performed. 12 Introduction of a cationic Arg residue into the aromatic-rich anionic ␣/ binding site of AChR hinders stabilization of cationic ACh and markedly reduces apparent agonist affinity. In addition, the mutation hinders isomerization of the receptor from the closed to the open state, slows the apparent opening rate, speeds the apparent closing rate, and reduces open channel probability. The altered channel kinetics predict a short duration and low amplitude of the endplate potential that falls short of the threshold for activating postsynaptic voltage-gated Na channels. Finally, the very low opening probability of the mutant receptor over a range of ACh concentrations explains the limited clinical response to pyridostigmine.
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